[1] Gnecchi M, Melo LG.Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium.Methods Mol Biol. 2009;482:281-294.
[2] Noiseux N, Gnecchi M, Lopez-Ilasaca M,et al.Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation.Mol Ther. 2006;14(6):840-850.
[3] Zhu W, Chen J, Cong X, et al.Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells. 2006;24(2):416-425.
[4] Xu J, Qian J, Xie X,et al.High density lipoprotein protects mesenchymal stem cells from oxidative stress-induced apoptosis via activation of the PI3K/Akt pathway and suppression of reactive oxygen species.Int J Mol Sci. 2012; 13(12):17104-17120.
[5] He Z, Li H, Zuo S,et al.Transduction of Wnt11 promotes mesenchymal stem cell transdifferentiation into cardiac phenotypes.Stem Cells Dev. 2011;20(10):1771-1778.
[6] Hu X, Yu SP, Fraser JL,et al.Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis.J Thorac Cardiovasc Surg. 2008; 135(4):799-808.
[7] Rosová I, Dao M, Capoccia B,et al.Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.Stem Cells. 2008;26(8):2173-2182.
[8] Gnecchi M, He H, Liang OD,et al.Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.Nat Med. 2005;11(4):367-368.
[9] Gnecchi M, He H, Melo LG,et al.Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction.Stem Cells. 2009;27(4):971-979.
[10] Mirotsou M, Zhang Z, Deb A,et al.Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair.Proc Natl Acad Sci U S A. 2007;104(5):1643-1648.
[11] Koyanagi M, Haendeler J, Badorff C,et al.Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells.J Biol Chem. 2005; 280(17):16838-16842.
[12] Xiang G, Yang Q, Wang B,et al.Lentivirus-mediated Wnt11 gene transfer enhances Cardiomyogenic differentiation of skeletal muscle-derived stem cells.Mol Ther. 2011;19(4): 790-796.
[13] Flaherty MP, Abdel-Latif A, Li Q,et al.Noncanonical Wnt11 signaling is sufficient to induce cardiomyogenic differentiation in unfractionated bone marrow mononuclear cells.Circulation. 2008;117(17):2241-2252.
[14] He Z, Li H, Zuo S,et al.Transduction of Wnt11 promotes mesenchymal stem cell transdifferentiation into cardiac phenotypes.Stem Cells Dev. 2011;20(10):1771-1778.
[15] Skubis-Zegad?o J, Stachurska A, Ma?ecki M.Vectrology of adeno-associated viruses (AAV).Med Wieku Rozwoj. 2013; 17(3):202-206.
[16] Zincarelli C, Soltys S, Rengo G,et al.Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.Mol Ther. 2008;16(6):1073-1080.
[17] 向阳,马依彤,杨毅宁,等.重组9型腺相关病毒载体转染小鼠心脏及对心功能的影响[J].中华微生物学和免疫学杂志,2009, 29(10): 899-902.
[18] Pavo N, Charwat S, Nyolczas N,et al.Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences.J Mol Cell Cardiol. 2014;75:12-24.
[19] Heidt T, Courties G, Dutta P,et al.Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction.Circ Res. 2014;115(2):284-295.
[20] Zsebo K, Yaroshinsky A, Rudy JJ,et al.Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114(1):101-108.
[21] Fisher SA, Dorée C, Brunskill SJ,et al.Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis.PLoS One. 2013;8(6):e64669.
[22] Rostovskaya M, Anastassiadis K.Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment.PLoS One. 2012;7(12):e51221.
[23] Zacharaki D, Lagoudaki R, Touloumi O,et al.Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells isolated from experimental autoimmune encephalomyelitis mice.J Mol Neurosci. 2013;51(2):282-297.
[24] Wang M, Yu Q, Wang L,et al.Distinct patterns of histone modifications at cardiac-specific gene promoters between cardiac stem cells and mesenchymal stem cells.Am J Physiol Cell Physiol. 2013;304(11):C1080-1090.
[25] Cucchiarini M, Madry H.Overexpression of human IGF-I via direct rAAV-mediated gene transfer improves the early repair of articular cartilage defects in vivo.Gene Ther. 2014;21(9): 811-819.
[26] Hirsch ML, Samulski RJ.AAV-mediated gene editing via double-strand break repair.Methods Mol Biol. 2014;1114: 291-307.
[27] Shin JH, Nitahara-Kasahara Y, Hayashita-Kinoh H,et al. Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction.Gene Ther. 2011;18(9):910-919.
[28] Pacak CA, Byrne BJ.AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.Mol Ther. 2011; 19(9):1582-1590.
[29] Konkalmatt PR, Beyers RJ, O'Connor DM,et al.Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling.Circ Cardiovasc Imaging. 2013;6(3): 478-486.
[30] 纪伟宁,杨毅宁,马依彤,等.含不同启动子的重组9型腺相关病毒载体转染大鼠心肌细胞表达效率的差异[J].中华微生物和免疫学杂志,2011,31(9):830-832.
[31] 马翔,姚永钊,赵爱超,等. 腺相关病毒介导血小板源性生长因子基因转染间充质干细胞的研究[J].中华实验外科杂志,2012, 29(10):2094.
[32] Ellis BL, Hirsch ML, Barker JC,et al.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype.Virol J. 2013;10:74.
[33] Chakrabarty P, Rosario A, Cruz P,et al.Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.PLoS One. 2013;8(6):e67680.
[34] Teschendorf C, Warrington KH Jr, Siemann DW,et al.Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus.Anticancer Res. 2002;22(6A): 3325-3330.
[35] Qin JY, Zhang L, Clift KL,et al.Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One. 2010;5(5):e10611. |